Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

1. Neurocrine's Q4 adjusted EPS of $1.69 beats expectations. 2. Sales missed consensus at $627.7 million, indicating potential revenue challenges. 3. Ingrezza net sales grew 23%, signaling strong patient demand. 4. 2025 revenue guidance for Ingrezza is slightly conservative. 5. Analysts express mixed views on NBIX, reflecting near-term pressures.